Q2 2024 · —
Revenue—
Net Income-$17.05M-$17.05M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$19.01-$19.01 no prior Q2 2023 on fileN/M vs Q1 2024
Operating Income-$19,750,000—
Operating Cash Flowderived-$12,908,000—
Free Cash Flowderived-$12,927,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Net Income | -$17.05M | -$9.29M |
| EPS Diluted | -$19.01 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR